THE APPROVED USE, BENEFIT, AND RISKS
PT-141 is bremelanotide, a shot that begins with the brain.
Bremelanotide acts on desire in the brain, not blood flow. This page covers its approved use, harms, and Phase 3, the last major tests before approval.
What the drug may change and what can go wrong
PT-141 is a lab-made piece of protein called bremelanotide. It changes brain regions that help form sexual desire.
The FDA gave one approval in June 2019. It covers lasting low desire that upsets some women before they reach menopause.
In large trials, average desire rose only a little. Nausea was common, and PT-141 use in men hasn't been approved.
This page gives you the main facts and limits. You can follow the linked pages to check results and harms in plain words.
What Is PT-141, and what part of the body does it affect?
PT-141, under the drug name bremelanotide, has seven protein building blocks joined in a ring. It acts in parts of your brain that shape sexual desire [1].
The drug is based on a hormone made inside your body. That hormone carries chemical messages through you and can affect appetite, skin color, and sexual interest [8].
On June 21, 2019, the FDA approved bremelanotide [7]. The label describes PT-141 and bremelanotide as the same drug [6].
The approval covers a finished shot, not loose research powder. Keep that in mind with products sold online.
Many drugs for erection trouble help the penis fill with blood. PT-141 begins earlier, where your brain helps create wanting.
Large studies found a real but slight average benefit. You also need to weigh nausea and the blood-pressure warning.
What the PT-141 peptide contains
Seven small protein building blocks, called amino acids, form the PT-141 peptide. Their ring shape slows the body's breakdown of the drug [6].
The ring lasts longer than a loose chain [6]. The medicine resembles an older lab compound, but one end was changed [6].
That change helps the drug reach brain sites linked with desire. The approved medicine is a finished bremelanotide shot [7].
Powder sold as "PT-141 research chemical" is separate from the approved drug. A label cannot prove its contents, strength, or cleanliness [6].
What PT-141 changes in the brain and what it does not
PT-141 affects brain regions involved in wants and urges [1]. Scientists give related brain-cell switches numbers; switch 4 may help free dopamine, a chemical tied to wanting sex [3].
After a dose, erections occurred in rats and monkeys, and activity rose in some brain cells [1]. Female-rat findings were more exact.
Female rats sought out males more, yet normal mating reflexes and general movement stayed unchanged [2]. That points to more sexual seeking, not a rise in all activity.
Women bothered by low desire said their desire rose and their distress eased [3]. PT-141 neither raises testosterone nor acts like blood-flow medicines.
The common questions about PT-141 page gives you short answers. The research page explains how PT-141 works and where proof ends.
What PT-141 is approved to treat and who is left out
Bremelanotide has FDA approval for one narrow use. It may treat a later loss of desire that lasts, begins before menopause, and causes real upset [7].
Two Phase 3 trials, the last major tests before approval, measured the benefit. A year-long follow-up watched safety for a longer time [3][4].
Some early work produced erections in men, yet did not establish a treatment [1]. The PT-141 for men page explains what those unapproved studies found and their limits.
Women after menopause, erection trouble, and general sexual performance all sit outside the approval [9]. Claims for those uses go past what the FDA accepted.
You can read how PT-141 works and see PT-141 dosage in the research. Before you weigh the slight possible gain, read the heart warning and risk of skin or mouth tissue growing darker.
What personal reports can say and what trials can prove
People online describe wanted effects, no effect, and hard side effects. The benefits and risks page separates those stories from findings that controlled studies have tested.